Project Grant R41AG084429
Award Date
9/25/24
Completion Date
8/31/25
Dollars Obligated
$500K
Federal Agency
National Institute on Aging
Awardee
Alzarrok Bio LLC (EDXPGR42RLC4)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK 73110, USA
Similar Awards
This Project Grant award from the National Institute on Aging (part of the National Institutes of Health, CFDA# 93.866 Aging Research) provides $1,041,646 to Cenna Biosciences Inc. to support early clinical development of a novel peptide drug candidate, modified P8 (MP8), for the treatment of Alzheimer's disease. The funding will be used to conduct chemistry, manufacturing, and controls (CMC) activities to prepare for a first-in-human clinical study, hold a pre-IND meeting with the FDA, submit...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $504,732 to Aphios Corp, a minority-owned biotechnology company, to develop a novel Alzheimer's disease therapeutic. The project aims to nanoencapsulate an anti-CCR5 drug into targeted and non-targeted nanoparticles, and evaluate their impact on brain inflammation and blood-brain barrier penetration as a potential treatment for Alzheimer's disease. In Phase I, the company will...
This $499,441 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Acepre, LLC aims to develop a novel brain-targeted delivery system for N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The proposed research includes evaluating the toxicity and pharmacokinetic properties of TN-NAC in mice (Specific Aim 1) and testing the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model (Specific Aim 2). Successful completion of these...
This Project Grant award from the National Institute on Aging (NIA), under CFDA 93.866 Aging Research, provides $2,432,649 to Virogenics, Inc., a biotechnology company in San Diego, California, to advance the development of their novel Alzheimer's disease drug candidate, CMS121. The funding will support two critical components: 1) a 13-week toxicology study in rats and dogs to enable longer-term clinical trials of CMS121 in human patients with mild to moderate Alzheimer's disease, and 2) the...
This $499,968 Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) supports the development of novel, potent, and selective Kv1.3 potassium channel inhibitors as potential therapeutics for Alzheimer's disease. The awardee, Hager Biosciences, LLC, aims to further characterize and optimize lead compounds that have demonstrated efficacy in inhibiting Kv1.3 channels, which play a key role in neuroinflammatory processes associated with...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $509,038 to Ceiba Bio Inc. to develop a blood-based exercise mimetic as a potential treatment for Alzheimer's disease and related dementias. The project aims to identify lead recombinant human GPLD1 molecules, conduct in vivo pharmacokinetic profiling, and test the disease-modifying effects of GPLD1 in an Alzheimer's mouse model. Successful completion of these aims is expected to advance the...
This federal Project Grant award of $994,436 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Transchromix LLC supports research to develop novel brain-penetrant drugs that target the histone methyltransferase G9A for the treatment of Alzheimer's disease. The grant funding will enable the research team to further investigate the noncanonical, translation regulatory function of G9A in Alzheimer's disease pathogenesis and evaluate the mechanism of action for the...
This $313,000 Project Grant award from the National Institute on Aging (part of the Department of Health and Human Services) under the Aging Research program (CFDA 93.866) supports research to discover small molecule inhibitors that can disrupt the protein-protein interaction between the p38 and MK2 proteins. This interaction plays a central role in pro-inflammatory signaling, which is a major hallmark of Alzheimer's disease. The researchers at Emory University will combine high-throughput...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $295,000 to Florida International University (FIU) to develop and test a novel nanogel system for the treatment of Alzheimer's disease (AD). The proposed nanogels are designed to cross the blood-brain barrier and target key biomarkers of AD, including amyloid-beta (Aβ) aggregation, neuroinflammation, and oxidative stress. This project aims to improve the nanogel's ability to transmigrate...
This $3,357,206 Project Grant award, funded by the National Institute on Aging (CFDA 93.866 - Aging Research), supports the clinical evaluation of a novel compound, BMS-984923, for the treatment of Alzheimer's disease (AD). Allyx Therapeutics Inc. has obtained an exclusive license for the use of BMS-984923 in neurodegenerative diseases. The project seeks to develop this disease-modifying compound by targeting the underlying mechanism of synapse loss, which is tightly correlated with cognitive...